Maywufa (1731) reported revenue of NT$162.9 million for Oct 2026, +21.1% year on year and +14.5% from the previous month. Revenue for Jan–Oct 2026 was NT$1.44 billion (+10.5% year on year).
Year-on-year revenue growth: 14 months in a row. →
In Oct 2026, it ranked No. 51 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$162.9 million | +21.1% | +14.5% |
| Sep 2026 | NT$142.3 million | +9.7% | +6.8% |
| Aug 2026 | NT$133.2 million | +18.0% | -9.7% |
| Jul 2026 | NT$147.5 million | +13.8% | +11.8% |
| Jun 2026 | NT$131.9 million | +2.5% | -3.9% |
| May 2026 | NT$137.1 million | +13.1% | +3.0% |
| Apr 2026 | NT$133.1 million | +6.7% | -3.1% |
| Mar 2026 | NT$137.4 million | +15.1% | +7.6% |
| Feb 2026 | NT$127.7 million | +3.7% | -31.8% |
| Jan 2026 | NT$187.2 million | +4.2% | +28.6% |
| Dec 2025 | NT$145.6 million | +14.7% | +8.2% |
| Nov 2025 | NT$134.6 million | +4.8% | +0.1% |
| Oct 2025 | NT$134.6 million | +11.5% | +3.7% |
| Sep 2025 | NT$129.7 million | +11.8% | +14.8% |
| Aug 2025 | NT$113 million | -3.7% | -12.8% |
| Jul 2025 | NT$129.6 million | +9.4% | +0.7% |
| Jun 2025 | NT$128.7 million | +8.4% | +6.1% |
| May 2025 | NT$121.2 million | +2.0% | -2.9% |
| Apr 2025 | NT$124.8 million | +10.6% | +4.5% |
| Mar 2025 | NT$119.4 million | +6.9% | -3.1% |
| Feb 2025 | NT$123.2 million | +9.3% | -31.5% |
| Jan 2025 | NT$179.8 million | -1.9% | +41.6% |
| Dec 2024 | NT$127 million | +9.0% | -1.1% |
| Nov 2024 | NT$128.4 million | +10.9% | +6.4% |
| Oct 2024 | NT$120.7 million | +15.5% | +4.0% |
Jan–Oct 2026 cumulative: NT$1.44 billion (+10.5% YoY)
Other Biotech & Medical companies
Compare with peers: Maywufa vs PEC / Maywufa vs Lotus Pharm / Maywufa vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本期美髮新品上市深受歡迎,營收較去年同期大幅成長逾21%
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16